InnerMost Mixer — From Policy to Practice: Inside the Executive Order with Attorney Hadas Alterman
An evening of connection with clinicians and leaders shaping the future of therapy in New York City, featuring Hadas Alterman, a leading legal advocate in the psychedelic industry
Once a month, InnerMost hosts the InnerMost Mixer—an intimate gathering for therapists, psychiatrists, researchers, and medical professionals to connect, learn, and grow in community. We welcome those practicing or simply curious about psychedelic-assisted therapy and integrative mental health.
Schedule
7:00 PM – Doors Open*
*Please arrive no earlier than 7pm so as to not disrupt patients
7:30 PM – Fireside Chat with Hadas Alterman & Casey Paleos, MD
8:15 PM – Socialize & Connect
On April 18, 2026, President Trump signed an executive order directing the FDA to fast-track review of psychedelic compounds—including psilocybin and ibogaine—and allocating $50 million toward federal-state research collaboration. The order directs the FDA Commissioner to provide priority vouchers to appropriate psychedelic drugs that have received Breakthrough Therapy designations, ensuring that red tape does not delay review of potential therapies. It also opens new pathways for patient access under the Right to Try Act.
For clinicians working in this space—or preparing to—this isn't abstract policy news. It's a signal that the legal and regulatory ground beneath our work is actively changing. Understanding what that means, what it protects, what it doesn't, and what it opens up, is suddenly of urgent relevance.
Join us for an intimate evening of conversation at InnerMost with Hadas Alterman, one of the foremost legal minds in the psychedelic field, and someone with a uniquely close vantage point on this moment. Her partner helped write the executive order.
We'll gather, connect, and dig into the questions that matter to practitioners: What does this order actually change? What remains uncertain? What should clinicians be paying attention to as the landscape evolves? And what does it mean to practice with integrity inside a regulatory environment that's still being written?
About Hadas Alterman
Hadas Alterman is a leading legal advocate in the psychedelic industry, with experience advising businesses, investors, and nonprofits navigating the emerging regulated market. As co-founder of Plant Medicine Law Group LLP, she built a boutique firm to support psychedelic-assisted therapy clinics, retreat centers, training programs, drug development companies, and media organizations.
Hadas has played an active role in shaping psychedelic legalization at the state level, as a member of the Oregon Psilocybin Advisory Board for Measure 109 and the Natural Medicine Advisory Board for Proposition 112 in Colorado. She was also a Founding Board Member of the Psychedelic Bar Association and previously served as Director of Communications & Policy for the American Psychedelic Practitioners Association.
Her work has included advising ketamine-assisted therapy clinics, psilocybin retreat operators, and psychedelic research organizations, and she has provided legal risk assessment for nonprofits focused on access, integration support, and Indigenous rights advocacy in psychedelic medicine.
She is based in New York, with a J.D. from Berkeley Law and a B.A. in Community Studies and Agriculture & Social Justice from UC Santa Cruz. Learn more about Hadas and her work.
To receive updates on future events hosted by InnerMost, as well as our clinical services, educational programming, and training opportunities, visit www.innermost.one and sign up for our newsletter.